In a randomised cross-over study of 17 participants with non-insulin-treated type 2 diabetes, 5 weeks of empagliflozin vs NPH insulin at similar glucose control gave higher beta cell glucose sensitivity, insulin sensitivity and disposition index.
RCTn = 17
Thirumathyam et al. Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator